Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • MOG (35-55): Gold-Standard Peptide for Experimental Autoi...

    2026-01-01

    MOG (35-55): Gold-Standard Peptide for Experimental Autoimmune Encephalomyelitis Modeling

    Executive Summary: MOG (35-55) is a peptide fragment derived from human myelin oligodendrocyte glycoprotein, used as the benchmark inducer in experimental autoimmune encephalomyelitis (EAE) models of multiple sclerosis (MS) (Xu et al., 2025). The A8306 kit from APExBIO offers high purity and batch reproducibility for consistent immune responses (APExBIO product page). MOG (35-55) robustly activates both T and B cell compartments, triggering relapsing-remitting neurological disease that recapitulates key MS pathology (see also). The peptide is soluble at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO, and requires specific storage and handling protocols for optimal performance. Benchmarking studies confirm its reliability for modeling autoimmune neuroinflammation and for evaluating intervention strategies (Xu et al., 2025).

    Biological Rationale

    MOG (35-55) is a 21-amino-acid peptide fragment (residues 35–55) from the extracellular domain of human myelin oligodendrocyte glycoprotein (MOG), a central nervous system (CNS) protein in the immunoglobulin superfamily (APExBIO). The MOG protein is highly immunogenic and accessible to antibodies and immune cells in demyelinating diseases such as MS. When MOG (35-55) is administered to susceptible mouse strains with complete Freund's adjuvant (CFA), it reliably induces EAE, the principal animal model for MS pathogenesis and therapy research (Xu et al., 2025). This model recapitulates the relapsing-remitting neurological deficits, demyelination, and immune infiltration characteristic of human MS (see Immuneland). MOG (35-55) is thus critical for dissecting autoimmune mechanisms, testing immunomodulatory agents, and evaluating neuroinflammation biomarkers.

    Mechanism of Action of MOG (35-55)

    MOG (35-55) acts as a potent immunogen that triggers both cell-mediated and humoral immune responses. The peptide is processed and presented by MHC class II molecules (notably HLA-DR2 in humanized models) on antigen-presenting cells. This presentation activates CD4+ T cells, which differentiate into pro-inflammatory Th1 and Th17 subsets. These T cells migrate into the CNS, release cytokines, and recruit additional immune cells, establishing a neuroinflammatory environment (Xu et al., 2025). B cells specific for MOG (35-55) produce autoantibodies that contribute to demyelination. In vitro studies show that MOG (35-55) induces dose-dependent decreases in total protein concentration and increases NADPH oxidase and MMP-9 activities, implicating oxidative stress and extracellular matrix remodeling in disease development. These pathways mirror key aspects of human MS pathology (see mechanistic review).

    Evidence & Benchmarks

    • MOG (35-55) consistently induces EAE in C57BL/6 and HLA-DR2-transgenic mice at 50–150 μg/dose, with severity correlating to dose and strain (Xu et al., 2025).
    • The peptide elicits robust T cell (especially Th17 and Th1) and B cell responses, driving demyelination and clinical paralysis (Xu et al., 2025).
    • Inhibition of PARP7, a negative regulator of interferon signaling, ameliorates MOG (35-55)-induced EAE, confirming the model's translational relevance (Xu et al., 2025).
    • APExBIO's MOG (35-55) (A8306) product is validated for solubility (≥32.25 mg/mL in water, ≥86 mg/mL in DMSO) and reproducible clinical scores in blinded animal studies (APExBIO).
    • Comparative studies show the peptide's effects are not mimicked by scrambled or irrelevant peptides, confirming specificity (Immuneland).

    This article extends existing reviews (e.g., Gold Standard Peptide for EAE) by providing updated mechanistic and benchmark data from recent translational studies, clarifying the peptide's predictive value for MS research.

    Applications, Limits & Misconceptions

    MOG (35-55) is the principal reagent for:

    • Inducing chronic or relapsing-remitting EAE in mice for preclinical MS research.
    • Evaluating neuroinflammation, demyelination, and immune cell function in vivo.
    • Screening immunomodulatory therapies, such as PARP7 inhibitors, that target type I interferon or T cell pathways.
    • Modeling blood-brain barrier permeability and matrix metalloproteinase (MMP-9) activity in neuroinflammation.

    However, the peptide's utility is constrained by species and strain dependence, and it does not model all aspects of human MS (e.g., progressive forms, environmental triggers).

    Common Pitfalls or Misconceptions

    • Not all mouse strains are susceptible: MOG (35-55) induces EAE in C57BL/6 and HLA-DR2-transgenic mice, but not in BALB/c or SJL strains; strain selection is critical.
    • Peptide purity and solubility are essential: Impurities or insolubility can cause inconsistent or failed induction; follow APExBIO's handling recommendations strictly.
    • Does not model all MS subtypes: The EAE model induced by MOG (35-55) primarily mimics relapsing-remitting MS, not primary progressive forms.
    • Adjuvant and dose are decisive: Efficacy depends on co-administration with CFA and correct dosing (50–150 μg/mouse).
    • Autoimmune specificity: Control peptides do not induce EAE, confirming specificity but requiring careful experimental design.

    Workflow Integration & Parameters

    For optimal results, dissolve MOG (35-55) at ≥32.25 mg/mL in sterile water or ≥86 mg/mL in DMSO. Ethanol is not recommended due to insolubility. Prepare working stocks at 0.50 mg/mL in sterile water, using gentle warming (up to 37°C) and ultrasonic bath if needed to enhance dissolution (APExBIO). Store desiccated aliquots at -20°C and use within one week to prevent degradation. For EAE induction, inject 50–150 μg subcutaneously per mouse, typically emulsified with CFA containing Mycobacterium tuberculosis H37Ra. Monitor animals for weight loss and neurological scores daily for up to 30 days post-injection. For in vitro assays, titrate peptide concentrations to assess dose-dependent effects on immune cell activation, protein content, NADPH oxidase, and MMP-9 activity. The A8306 kit from APExBIO provides validated peptide suitable for these workflows.

    Conclusion & Outlook

    MOG (35-55) remains the gold-standard peptide for induction of EAE in preclinical MS research, enabling reproducible modeling of autoimmune neuroinflammation and demyelination. Recent advances, such as the demonstration that PARP7 inhibition can alleviate MOG (35-55)-induced EAE via modulation of interferon signaling, highlight the ongoing translational relevance of this model (Xu et al., 2025). For robust, high-fidelity autoimmune disease modeling, researchers should employ validated products such as APExBIO's MOG (35-55) (A8306) in conjunction with rigorous workflow and animal monitoring protocols.